The Pfizer men B shot grabs an approval-speeding designation just two months after GSK's Bexsero—Trumenba's archrival—got the same boost.
Thanks to widely used egg-based manufacturing, this fall's flu vaccine will be only 20% effective against the dominant strain, according to a study.
WHO advisers said Sanofi's Dengvaxia should only be used after a diagnostic confirms a prior infection. But fast and reliable tests don't exist.
Here is some other vaccine news of note for the week.
Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.
A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.
The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.
Merck's Gardasil 9 has been on an upward trajectory, but high global demand for the HPV shot has created a shortage for U.K. private clinics.
At €350 million, Sanofi's new Canadian vaccine plant will be one of the largest investments ever by the company in a single facility.
The FDA is evaluating the possibility of prosecuting those involved in rogue herpes vaccine research led by a Southern Illinois University professor.